Liquidia Corporation is set to proceed with the commercial launch of its inhalation powder, YUTREPIA, following a legal victory against United Therapeutics. On May 30, 2025, the U.S. District Court for the Middle District of North Carolina denied United Therapeutics' request for a preliminary injunction and a temporary restraining order. United Therapeutics had sought to block Liquidia from commercializing YUTREPIA, alleging infringement of their patent. The court's decision was influenced by the conclusion that United Therapeutics is unlikely to succeed on the merits of its claims. With the denial of this request, Liquidia is clear to begin shipping YUTREPIA to specialty pharmacies, just days after receiving FDA approval for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。